Court dismisses Bayer’s appeal on timing of patent and retroactive eligibility
The Federal Court of Appeal has dismissed an appeal by pharmaceutical manufacturer Bayer regarding a subsequent entry version of the drug aflibercept by a competitor that did not cite the appellant’s...To view the full article, register now.
Already a subscriber? Click here to view full article